Sedation Detox

7-OH and kratom: what the sedation detox programs say

7-OH (7-hydroxymitragynine) occurs in small amounts in kratom leaf and is now sold in concentrated tablets, gummies and drinks. The FDA says it causes physical dependence and withdrawal like other opioids. Four of the seven programs on this site address 7-OH or kratom on their websites. This page sets out what each one says.

Updated October 20, 2026. Sources are linked in the text.

  1. Jul 2025The FDA recommends scheduling 7-OH as a controlled substance.
  2. Jul 2026The DEA announces it intends to place 7-OH above a set level in Schedule I.
  3. Aug 2026Three related compounds go into Schedule I by temporary order.
  4. Oct 2026The DEA replaces its July notice, using a new threshold from HHS.
  5. Nov 13, 2026Earliest date the temporary order for 7-OH can be published.
Federal steps so far. 7-OH itself is not yet a controlled substance.

What 7-OH is

7-OH, short for 7-hydroxymitragynine, is one of the alkaloids in the leaves of the kratom tree (Mitragyna speciosa). In natural leaf it is a minor part: less than 2 percent of the total alkaloid content, according to the FDA. Products sold as 7-OH contain far more, and the FDA says the added 7-OH is likely made chemically from mitragynine, kratom's main alkaloid, or from kratom extract.

The FDA's July 2025 assessment describes 7-OH as an opioid that acts on the same receptor as morphine and fentanyl. It says 7-OH produces respiratory depression, physical dependence and withdrawal symptoms like those of classical opioids, and that repeated or prolonged use would lead to tolerance and dependence, and potentially to addiction. FDA assessment of 7-OH, July 2025.

Federal status in October 2026

As of October 20, 2026, 7-OH is not a federally controlled substance. The DEA has said it intends to place concentrated 7-OH in Schedule I, the federal category for drugs with no accepted medical use, by temporary order.

  • July 29, 2025. The FDA recommended scheduling 7-OH under the Controlled Substances Act and said it was not focused on natural kratom leaf products. HHS press release.
  • July 6, 2026. The DEA published a notice of intent to place 7-OH above a set concentration in Schedule I. Federal Register.
  • August 26, 2026. The DEA placed three related compounds, mitragynine pseudoindoxyl, MGM-15 and MGM-16, in Schedule I by temporary order, in effect until August 26, 2028. Federal Register.
  • October 14, 2026. The DEA withdrew the July notice and published a new one covering 7-OH and mitragynine pseudoindoxyl, based on a threshold the Department of Health and Human Services recommended on October 8. It says the temporary order will be published on or after November 13, 2026. Federal Register, Justice Department, October 9, 2026.

Under the October notice, a product would fall under Schedule I if it contains more than 1 milligram of 7-OH per gram, or per milliliter for liquids, or if it contains less than 100 times as much mitragynine as 7-OH. Mitragynine pseudoindoxyl counts toward the same limits. The Justice Department says the threshold is meant to separate products with trace amounts from products that were enhanced or concentrated, and the notice adds that neither HHS nor the DEA has found these substances safe to use below the threshold. Some states regulate kratom or 7-OH under their own laws, and those rules change often.

Dependence and withdrawal

The DEA's October notice cites data showing that chronic use of 7-OH has sent users to opioid detox clinics and to medication for opioid use disorder. Among the published cases it lists is a patient who needed inpatient buprenorphine stabilization for withdrawal from high doses of 7-OH. The notice also says the identity, purity and concentration of the active ingredients in 7-OH products are often unknown and inconsistent.

What each program's website says

Advanced Rapid Detox and All Opiates Detox describe the same procedure for 7-OH or kratom that they use for other opioids. The other programs either list 7-OH among the substances they treat or do not mention it.

Advanced Rapid DetoxFarmington Hills, MI

Has a page for 7-OH and kratom detox. Says it treats both with its usual protocol: an opiate reversal procedure under IV sedation in its ICU, where patients spend about 24 hours, as part of a 4-day stay, then naltrexone tablets or a Vivitrol injection. The FAQ on the same page gives 5 to 7 days.

Source: 7-OH and kratom page

All Opiates DetoxWyandotte, MI

Has a kratom detox page describing the same sedation procedure it uses for other opioids, followed by a naltrexone implant, and a separate page about 7-OH.

Sources: Kratom page, 7-OH page

Lists kratom (7-hydroxy) among the dependencies patients may be evaluated for, and has pages on 7-OH and kratom in its list of opiates.

Sources: Procedure page, 7-OH page

ANR ClinicFlorida

Lists kratom and 7-OH among the opioids ANR treats. Its 7-OH page says many patients arrive while still using 7-OH and that the team stabilizes their dose before the procedure.

Sources: Opioids treated, 7-OH page

Its list of drugs treated does not include kratom or 7-OH.

Source: Home page

MRODS and Rapid Drug Detox Center are not listed here because their websites were offline or under construction when we checked on October 20, 2026.

What reviewers mention

In the reviews summarized on this site, reviewers of Advanced Rapid Detox and ANR Clinic describe coming off 7-OH.

Questions to ask about 7-OH

  • How many patients have you treated for 7-OH or kratom? Ask whether the procedure and the length of stay are the same as for other opioids.
  • Does the price change for 7-OH? Ask for the all-in price for your situation in writing.
  • What should I tell you about what I take? Product names and how much you take a day help, since strength varies between products. Mention any other opioids, alcohol or sedatives as well.
  • Which naltrexone do I leave with, and for how long?

More in questions to ask before you pay a deposit. If you also take Suboxone or methadone, see what each program requires.